enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Rhea-AI Summary
enVVeno Medical (NASDAQ: NVNO) reported second quarter 2026 results and highlighted FDA Investigational Device Exemption (IDE) approval to begin the TAVVE pivotal trial of its enVVe first-in-class, minimally invasive replacement venous valve for severe deep chronic venous insufficiency (CVI). The pivotal study is expected to start enrolling during the second half of 2026 and ultimately enroll about 230 patients across up to 40 U.S. sites.
The company expanded its intellectual property with a new U.S. patent covering key enVVe components. enVVeno ended June 30, 2026 with approximately $21.5 million in cash and investments, which management believes will fund operations into the third quarter of 2027. Second quarter cash burn was $3.4 million, with an expected increase to $4–5 million per quarter in the second half of 2026 as TAVVE enrollment begins. Net loss was $3.6 million ($5.37 per share), compared to $6.7 million ($11.52 per share) a year earlier.
Positive
- FDA IDE approval for TAVVE pivotal trial of enVVe replacement venous valve
- Pivotal TAVVE study planned to enroll ~230 patients at up to 40 U.S. sites
- New U.S. patent obtained covering key components of the enVVe System
- Quarter-end cash and investments of $21.5 million as of June 30, 2026
- Management projects cash runway extending into the third quarter of 2027
- Quarterly net loss reduced to $3.6 million from $6.7 million year over year
Negative
- Second quarter 2026 net loss of $3.6 million, or $5.37 per share
- Second quarter 2026 cash burn of $3.4 million
- Cash burn expected to rise to $4–5 million per quarter in second half 2026
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 earnings report | Positive | +1.5% | Reported Q1 results while advancing FDA IDE approval and maintaining Q3 2027 cash runway. |
| Mar 27 | FY2025 earnings report | Positive | +0.8% | Reported narrower annual loss, reduced R&D expense, and planned pivotal trial progress. |
| Oct 31 | Q3 earnings report | Positive | +1.1% | Reported lower net loss and continued enVVe development alongside VenoValve regulatory proceedings. |
| Aug 01 | Q2 earnings report | Positive | +5.6% | Reported clinical progress and positive interim VenoValve data despite higher year-over-year net loss. |
| Aug 01 | Q2 earnings report | Positive | -0.9% | Reported lower net loss and positive interim venous-ulcer data with continued FDA application progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings events produced four positive 24-hour reactions and one negative reaction, indicating mostly aligned but not uniform responses.
Key Terms
ide approval regulatory
pivotal trial medical
transcatheter medical
chronic venous insufficiency medical
bioprosthetic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027
IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the TAVVE® pivotal trial for its enVVe® System, a first-in-class, minimally invasive replacement venous valve for patients suffering from severe deep chronic venous insufficiency (CVI).
Second Quarter 2026 Highlights
Achieved first-ever FDA IDE approval for a U.S. pivotal study evaluating a transcatheter replacement venous valve for severe deep CVI.
TAVVE pivotal trial expected to commence during the second half of 2026, representing a major value-driving catalyst. The study will ultimately enroll approximately 230 patients across up to 40 U.S. clinical sites.
Expanded intellectual property portfolio with a new U.S. patent covering key components of the enVVe System, further strengthening the Company's competitive moat ahead of pivotal development.
Maintained a strong balance sheet, ending the quarter with approximately
$21.5 million in cash and investments, which management believes will fund operations into the third quarter of 2027, including the planned initiation of the TAVVE pivotal study.Continued disciplined capital management, reducing quarterly net loss by approximately
46% year over year while advancing the Company's highest-priority clinical program.
"The second quarter represented a defining milestone for enVVeno, as we got the approval to move forward with the pivotal study for enVVe, our non-surgical replacement venous valve. enVVe has the potential to completely change the treatment trajectory for the 3 million U.S. patients in the U.S. that suffer from severe, deep venous CVI and have no effective treatment options," commented Rob Berman, Chief Executive Officer of enVVeno Medical.
"As we enter the second half of 2026, our focus is squarely on executing the TAVVE pivotal study, getting our clinical sites up and running, and treating the first patients," concluded Mr. Berman.
Summary of Financial Results for the Second Quarter 2026
As of June 30, 2026, the Company had total cash and investments of approximately
Cash burn for the second quarter was
Net loss for the second quarter of 2026 was
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire